| __timestamp | MannKind Corporation | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79383000 | 17986000 |
| Thursday, January 1, 2015 | 108402000 | 32480000 |
| Friday, January 1, 2016 | 46928000 | 68081000 |
| Sunday, January 1, 2017 | 74959000 | 169906000 |
| Monday, January 1, 2018 | 79716000 | 248932000 |
| Tuesday, January 1, 2019 | 74669000 | 354100000 |
| Wednesday, January 1, 2020 | 59040000 | 433300000 |
| Friday, January 1, 2021 | 77417000 | 583300000 |
| Saturday, January 1, 2022 | 91473000 | 752700000 |
| Sunday, January 1, 2023 | 94314000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and MannKind Corporation from 2014 to 2023. Over this period, Neurocrine Biosciences has seen a staggering increase in SG&A expenses, growing nearly 50 times from 2014 to 2023. In contrast, MannKind Corporation's expenses have remained relatively stable, with a modest increase of about 20% over the same period.
Neurocrine's significant rise in expenses, peaking at nearly $888 million in 2023, reflects its aggressive expansion and investment in research and development. Meanwhile, MannKind's more conservative financial strategy is evident in its consistent expenditure, which reached approximately $94 million in 2023. This divergence in financial strategies highlights the different paths these companies are taking in the biotech landscape.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Pfizer Inc. and MannKind Corporation
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Zoetis Inc. vs MannKind Corporation Trends and Insights
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or MannKind Corporation
Who Optimizes SG&A Costs Better? ACADIA Pharmaceuticals Inc. or MannKind Corporation